Complex Chemically Active Transdermal Emulsion System Systemically Delivering CBD for the Treatment of Dravet syndrome & Lennox-Gastaut syndrome Patients: A Clinical Perspective
Time: 9:00 am
day: Day Two
Details:
- Novel chemically active transdermal system used for systemic delivery of therapeutic concentrations of CBD and THC
- Review of in vivo patient bioavailability data including blood concentrations curves for delivery of CBD and THC over a 12-hour period
- Review of in vivo patient response in CBD clinical trials to treat Dravet syndrome and Lennox-Gastaut syndrome patients
